An anti-ovarian aging gel and a preparation method thereof

Abstract

The application belongs to the technical field of gel materials, and specifically discloses an anti-ovarian aging gel and a preparation method thereof, which comprises the following components in percentage by mass: 0.05-0.2% of lactic acid, 0.1-0.4% of a stabilizer, 0.2-0.6% of tocopherol acetate, 0.2-0.6% of 1,2-hexanediol, 0.3-0.6% of a sustained-release agent, 0.9-1.2% of hydrolyzed lupin protein, 0.8-1.6% of hydrolyzed royal jelly protein, 0.75-1.3% of cortex moutan extract, 1-1.5% of a thickening agent, 0.5-2% of gelatin, 0.5-1.2% of beeswax, and the balance of water. The composition disclosed in the application takes the hydrolyzed lupin protein, the hydrolyzed royal jelly protein and the cortex moutan extract as main active ingredients, and under the joint action of the lactic acid, the stabilizer, the tocopherol acetate, the 1,2-hexanediol, the sustained-release agent, the thickening agent, the gelatin and the beeswax, the gel obtained can effectively improve the content of progesterone and E2 and has a good anti-ovarian aging effect.

Description

Technical Field

[0001] This invention relates to the field of gel materials technology, specifically to an anti-ovarian aging gel and its preparation method. Background Technology

[0002] As a core reproductive endocrine organ unique to women, the ovary's physiological functions directly determine female reproductive capacity, endocrine homeostasis, and the aging process. Premature ovarian failure (POF) refers to a clinical syndrome in which women experience ovarian dysfunction before the age of 40. It is characterized by menstrual abnormalities, elevated gonadotropin levels, and fluctuating estrogen levels, severely impacting patients' fertility and quality of life.

[0003] In recent years, the incidence of premature ovarian failure (POF) has been increasing year by year and is affecting younger women. According to statistics, the global incidence of POF is about 1% to 3%. POF not only reduces the natural pregnancy rate to below 5%, but also causes multiple long-term health damages, including an accelerated loss of bone density of 2% to 4% per year and a three-fold increase in the risk of cardiovascular disease.

[0004] Currently, the main clinical treatment for premature ovarian failure is hormone replacement therapy (HRT). While HRT can alleviate symptoms related to low estrogen and improve quality of life, it cannot restore normal ovarian function or fulfill a patient's fertility requirements. Furthermore, long-term use of HRT carries safety risks, including a slight increase in the risk of breast cancer, venous thrombosis, and stroke.

[0005] Therefore, this application is submitted. Summary of the Invention

[0006] This invention provides an anti-ovarian aging gel and its preparation method. The gel described in this application can effectively increase the content of progesterone and E2, and has a good anti-ovarian aging effect.

[0007] The present invention solves its technical problem by adopting the following technical solution: An anti-ovarian aging gel comprises the following components by weight percentage: 0.05-0.2% lactic acid, 0.1-0.4% stabilizer, 0.2-0.6% tocopheryl acetate, 0.2-0.6% 1,2-hexanediol, 0.3-0.6% sustained-release agent, 0.9-1.2% hydrolyzed lupin protein, 0.8-1.6% hydrolyzed royal jelly protein, 0.75-1.3% peony bark extract, 1-1.5% thickener, 0.5-2% gelatin, 0.5-1.2% beeswax, and the balance being water.

[0008] As an embodiment of this application, the thickener is at least one selected from xanthan gum, microcrystalline cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, and methyl cellulose.

[0009] As an embodiment of this application, the stabilizer is carboxymethyl chitosan.

[0010] As an embodiment of this application, the sustained-release agent is β-cyclodextrin.

[0011] As an embodiment of this application, the preparation method of the peony bark extract is as follows: (1) Peony bark powder was subjected to supercritical extraction to obtain the extract; (2) The extract was separated by passing it through a macroporous adsorption resin and dried to obtain the peony bark extract.

[0012] As an embodiment of this application, the particle size of the peony bark powder is 50-500 mesh.

[0013] As an embodiment of this application, the supercritical extraction uses an ethanol solution with a volume concentration of 60-85% as an entrainer, CO2 as the extractant, a CO2 flow rate of 60-75 mL / min, an extraction temperature of 35-42℃, an extraction pressure of 18-24 MPa, and an extraction time of 50-100 min.

[0014] As an embodiment of this application, the separation of the extract by passing it through a macroporous adsorption resin specifically involves: passing the extract through the macroporous adsorption resin at a flow rate of 0.5~2 BV / h, eluting at a rate of 0.8~1.5 BV / h, washing with water for 0.8~1.5 BV, and then washing with an ethanol solution with a volume concentration of 60~85wt% for 1~2 BV, and collecting the ethanol eluent.

[0015] As an embodiment of this application, the macroporous adsorption resin is HPD-300 macroporous adsorption resin.

[0016] This application also provides a method for preparing an anti-ovarian aging gel, comprising the following steps: Stabilizer, gelatin, beeswax, slow-release agent, thickener and water are mixed evenly at 50~85℃, cooled to 30~45℃, and then lactic acid, tocopheryl acetate, hydrolyzed lupin protein, hydrolyzed royal jelly protein and peony bark extract are added and stirred evenly to obtain anti-ovarian aging gel.

[0017] The beneficial effects of the present invention are as follows: The composition described in this application uses hydrolyzed lupin protein, hydrolyzed royal jelly protein, and peony bark extract as the main active ingredients. With the combined action of lactic acid, stabilizer, tocopheryl acetate, 1,2-hexanediol, sustained-release agent, thickener, gelatin, and beeswax, a gel is obtained that can effectively increase the content of progesterone and E2 and has a good anti-ovarian aging effect. Detailed Implementation

[0018] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0019] In this invention, the technical features described in an open-ended manner include both closed-ended technical solutions composed of the listed features and open-ended technical solutions that include the listed features.

[0020] In this invention, numerical ranges are involved. Unless otherwise specified, the numerical ranges are considered continuous and include the minimum and maximum values ​​of the range, as well as every value between the minimum and maximum values. Furthermore, when the range refers to integers, it includes every integer between the minimum and maximum values ​​of the range. Additionally, when multiple ranges are provided to describe features or characteristics, the ranges may be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges to which they are included.

[0021] In this invention, there are no particular limitations on the specific dispersion and stirring methods.

[0022] Unless otherwise specified, all reagents or instruments used in this invention are commercially available conventional products. Unless otherwise specified, the raw materials used in each comparative example and the parallel experiments of each embodiment are the same commercially available products.

[0023] Hydrolyzed lupin protein: sourced from Shanghai Bosuo Industrial Co., Ltd.

[0024] Hydrolyzed royal jelly protein: sourced from Shanghai Hongjiu Enterprise Development.

[0025] This application provides an anti-ovarian aging gel comprising the following components by weight percentage: 0.05-0.2% lactic acid, 0.1-0.4% stabilizer, 0.2-0.6% tocopheryl acetate, 0.2-0.6% 1,2-hexanediol, 0.3-0.6% sustained-release agent, 0.9-1.2% hydrolyzed lupin protein, 0.8-1.6% hydrolyzed royal jelly protein, 0.75-1.3% peony bark extract, 1-1.5% thickener, 0.5-2% gelatin, 0.5-1.2% beeswax, and the balance being water.

[0026] The composition described in this application uses hydrolyzed lupin protein, hydrolyzed royal jelly protein, and peony bark extract as the main active ingredients. With the combined action of lactic acid, stabilizer, tocopheryl acetate, 1,2-hexanediol, sustained-release agent, thickener, gelatin, and beeswax, a gel is obtained that can effectively increase the content of progesterone and E2 and has a good anti-ovarian aging effect.

[0027] The hydrolyzed royal jelly protein is rich in royal jelly main protein and active small molecule peptides. It has natural plant estrogen activity, can bind to estrogen receptors to regulate the secretion of sex hormones in the body, downregulate the content of follicle-stimulating hormone and luteinizing hormone, increase hormone levels, repair the hypothalamic-pituitary-ovarian endocrine axis, and protect mitochondria of granulosa cells.

[0028] The hydrolyzed lupin protein is rich in highly active antioxidant peptides and amino acids, exhibiting excellent antioxidant activity. It can remove harmful oxidative substances, inhibit the expression of matrix metalloproteinases, stabilize the extracellular matrix structure of ovarian cells, and provide sufficient nutrient substrates for the growth and development of follicles and granulosa cells.

[0029] Among them, the peony bark extract has excellent antibacterial effects, can remove excess reactive oxygen free radicals in the body, enhance the body's antioxidant capacity, inhibit inflammatory signaling pathways, reduce the expression of inflammatory factors, alleviate local inflammatory response in the ovary, and block apoptosis of ovarian granulosa cells and oocytes by regulating apoptosis-related proteins.

[0030] This application combines hydrolyzed lupin protein, hydrolyzed royal jelly protein, and peony bark extract to create a complementary and synergistic effect from multiple dimensions, including anti-oxidation and anti-inflammation, regulation of endocrine levels, inhibition of ovarian cell apoptosis, and nourishment of follicle development. The three ingredients work together to increase the levels of progesterone and E2, thereby enhancing the gel's anti-premature ovarian failure effect.

[0031] The amount of lactic acid used is 0.05~0.2%, for example, it can be 0.05%, 0.06%, 0.08%, 0.1%, 0.12%, 0.15%, 0.18%, 0.2% or any two of these values.

[0032] The amount of stabilizer used is 0.1~0.4%, for example, it can be 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4% or any two of these values.

[0033] The amount of tocopherol acetate used is 0.2-0.6%, for example, it can be 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6% or any two of these values.

[0034] The amount of 1,2-hexanediol used is 0.2-0.6%, for example, it can be 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6% or any two of these values.

[0035] The amount of the sustained-release agent is 0.3-0.6%, for example, it can be 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6% or any two of these values.

[0036] The amount of hydrolyzed lupin protein used is 0.9-1.2%, for example, it can be 0.9%, 0.95%, 1%, 1.05%, 1.1%, 1.15%, 1.2% or any two of these values.

[0037] The amount of hydrolyzed royal jelly protein used is 0.8-1.6%, for example, it can be 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6% or any two of these values.

[0038] The amount of the peony bark extract used is 0.75~1.3%, for example, it can be 0.75%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3% or any two of these values.

[0039] The amount of the thickener is 1 to 1.5%, for example, it can be 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5% or any two of these values.

[0040] The amount of gelatin used is 0.5-2%, for example, it can be 0.5%, 0.6%, 0.8%, 1%, 1.2%, 1.5%, 1.8%, 2% or any two of these values.

[0041] The amount of beeswax used is 0.5-1.2%, for example, it can be 0.5%, 0.6%, 0.8%, 1%, 1.2% or any two of these values.

[0042] In some embodiments, the thickener is at least one of xanthan gum, microcrystalline cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, and methyl cellulose.

[0043] In some embodiments, the stabilizer is carboxymethyl chitosan.

[0044] In some embodiments, the sustained-release agent is β-cyclodextrin.

[0045] In some embodiments, the method for preparing the peony bark extract is as follows: (1) Peony bark powder was subjected to supercritical extraction to obtain the extract; (2) The extract was separated by passing it through a macroporous adsorption resin and dried to obtain the peony bark extract.

[0046] In some embodiments, the peony bark powder has a particle size of 50-500 mesh.

[0047] In some embodiments, the supercritical extraction uses an ethanol solution with a volume concentration of 60-85% as an entrainer, CO2 as the extractant, a CO2 flow rate of 60-75 mL / min, an extraction temperature of 35-42°C, an extraction pressure of 18-24 MPa, and an extraction time of 50-100 min.

[0048] In some embodiments, the separation of the extract by passing it through a macroporous adsorption resin specifically involves: passing the extract through the macroporous adsorption resin at a flow rate of 0.5~2 BV / h, eluting at a rate of 0.8~1.5 BV / h, washing with water for 0.8~1.5 BV, and then washing with an ethanol solution with a volume concentration of 60~85wt% for 1~2 BV, and collecting the ethanol eluent.

[0049] In some embodiments, the macroporous adsorption resin is HPD-300 macroporous adsorption resin.

[0050] One embodiment of this application provides a method for preparing an anti-ovarian aging gel, comprising the following steps: Stabilizer, gelatin, beeswax, slow-release agent, thickener and water are mixed evenly at 50~85℃, cooled to 30~45℃, and then lactic acid, tocopheryl acetate, hydrolyzed lupin protein, hydrolyzed royal jelly protein and peony bark extract are added and stirred evenly to obtain anti-ovarian aging gel.

[0051] The present application is further illustrated below with specific embodiments:

[0052] Example 1 An anti-ovarian aging gel comprises the following components by weight percentage: 0.12% lactic acid, 0.26% carboxymethyl chitosan, 0.4% tocopheryl acetate, 0.5% 1,2-hexanediol, 0.5% β-cyclodextrin, 1% hydrolyzed lupin protein, 1.5% hydrolyzed royal jelly protein, 0.9% peony bark extract, 1.35% hydroxypropyl cellulose, 1.4% gelatin, 1% beeswax, and the balance being water.

[0053] The preparation method of the peony bark extract is as follows: (1) Wash the peony bark, dry it to constant weight, and pulverize it to 200 mesh to obtain peony bark powder. Add the peony bark powder to the extraction vessel for supercritical extraction to obtain the extract. The supercritical extraction uses a 75% ethanol solution as the entrainer, CO2 as the extractant, CO2 flow rate of 70 mL / min, extraction temperature of 36℃, extraction pressure of 22 MPa, and extraction time of 80 min.

[0054] (2) The extract was passed through HPD-300 macroporous adsorption resin at a flow rate of 1.2 BV / h and the elution rate was 1.2 BV / h. It was first washed with water for 1.2 BV and then washed with 75 wt% ethanol solution for 1.5 BV. The ethanol eluent was collected, dried, and the peony bark extract was obtained.

[0055] The method for preparing the anti-ovarian aging gel includes the following steps: Carboxymethyl chitosan, gelatin, beeswax, β-cyclodextrin, hydroxypropyl cellulose, and water were mixed evenly at 65°C, cooled to 38°C, and then lactic acid, tocopheryl acetate, hydrolyzed lupin protein, hydrolyzed royal jelly protein, and peony bark extract were added and stirred evenly to obtain an anti-ovarian aging gel.

[0056] Example 2 An anti-ovarian aging gel comprises the following components by weight percentage: 0.05% lactic acid, 0.1% carboxymethyl chitosan, 0.2% tocopheryl acetate, 0.2% 1,2-hexanediol, 0.3% β-cyclodextrin, 0.9% hydrolyzed lupin protein, 1.6% hydrolyzed royal jelly protein, 0.75% peony bark extract, 1% hydroxypropyl cellulose, 2% gelatin, 1.2% beeswax, and the balance being water.

[0057] The preparation method of the peony bark extract is as follows: (1) Wash the peony bark, dry it to constant weight, and pulverize it to 200 mesh to obtain peony bark powder. Add the peony bark powder to the extraction vessel for supercritical extraction to obtain the extract. The supercritical extraction uses a 75% ethanol solution as the entrainer, CO2 as the extractant, CO2 flow rate of 70 mL / min, extraction temperature of 36℃, extraction pressure of 22 MPa, and extraction time of 80 min.

[0058] (2) The extract was passed through HPD-300 macroporous adsorption resin at a flow rate of 1.2 BV / h and the elution rate was 1.2 BV / h. It was first washed with water for 1.2 BV and then washed with 75 wt% ethanol solution for 1.5 BV. The ethanol eluent was collected, dried, and the peony bark extract was obtained.

[0059] The method for preparing the anti-ovarian aging gel includes the following steps: Carboxymethyl chitosan, gelatin, beeswax, β-cyclodextrin, hydroxypropyl cellulose, and water were mixed evenly at 65°C, cooled to 38°C, and then lactic acid, tocopheryl acetate, hydrolyzed lupin protein, hydrolyzed royal jelly protein, and peony bark extract were added and stirred evenly to obtain an anti-ovarian aging gel.

[0060] Example 3 An anti-ovarian aging gel comprises the following components by weight percentage: 0.2% lactic acid, 0.4% carboxymethyl chitosan, 0.6% tocopheryl acetate, 0.6% 1,2-hexanediol, 0.6% β-cyclodextrin, 1.2% hydrolyzed lupin protein, 0.8% hydrolyzed royal jelly protein, 1.3% peony bark extract, 1.5% hydroxypropyl cellulose, 0.5% gelatin, 0.5% beeswax, and the balance being water.

[0061] The preparation method of the peony bark extract is as follows: (1) Wash the peony bark, dry it to constant weight, and pulverize it to 200 mesh to obtain peony bark powder. Add the peony bark powder to the extraction vessel for supercritical extraction to obtain the extract. The supercritical extraction uses a 75% ethanol solution as the entrainer, CO2 as the extractant, CO2 flow rate of 70 mL / min, extraction temperature of 36℃, extraction pressure of 22 MPa, and extraction time of 80 min.

[0062] (2) The extract was passed through HPD-300 macroporous adsorption resin at a flow rate of 1.2 BV / h and the elution rate was 1.2 BV / h. It was first washed with water for 1.2 BV and then washed with 75 wt% ethanol solution for 1.5 BV. The ethanol eluent was collected, dried, and the peony bark extract was obtained.

[0063] The method for preparing the anti-ovarian aging gel includes the following steps: Carboxymethyl chitosan, gelatin, beeswax, β-cyclodextrin, hydroxypropyl cellulose, and water were mixed evenly at 65°C, cooled to 38°C, and then lactic acid, tocopheryl acetate, hydrolyzed lupin protein, hydrolyzed royal jelly protein, and peony bark extract were added and stirred evenly to obtain an anti-ovarian aging gel.

[0064] Comparative Example 1 The difference between Comparative Example 1 and Example 1 is that the amounts of hydrolyzed lupin protein, hydrolyzed royal jelly protein, and peony bark extract are not within the scope of this application (the total amount is the same), while everything else is the same.

[0065] An anti-ovarian aging gel comprises the following components by weight percentage: 0.12% lactic acid, 0.26% carboxymethyl chitosan, 0.4% tocopheryl acetate, 0.5% 1,2-hexanediol, 0.5% β-cyclodextrin, 0.45% hydrolyzed lupin protein, 2.5% hydrolyzed royal jelly protein, 0.45% peony bark extract, 1.35% hydroxypropyl cellulose, 1.4% gelatin, 1% beeswax, and the balance being water.

[0066] Comparative Example 2 The difference between Comparative Example 2 and Example 1 is that the amounts of hydrolyzed lupin protein, hydrolyzed royal jelly protein, and peony bark extract are not within the scope of this application (the total amount is the same), while everything else is the same.

[0067] An anti-ovarian aging gel comprises the following components by weight percentage: 0.12% lactic acid, 0.26% carboxymethyl chitosan, 0.4% tocopheryl acetate, 0.5% 1,2-hexanediol, 0.5% β-cyclodextrin, 1.5% hydrolyzed lupin protein, 0.4% hydrolyzed royal jelly protein, 1.5% peony bark extract, 1.35% hydroxypropyl cellulose, 1.4% gelatin, 1% beeswax, and the balance being water.

[0068] Comparative Example 3 The difference between Comparative Example 3 and Example 1 is that Comparative Example 3 does not contain hydrolyzed lupin protein (the total amount of hydrolyzed lupin protein, hydrolyzed royal jelly protein, and peony bark extract is the same), while everything else is the same.

[0069] An anti-ovarian aging gel comprises the following components by weight percentage: 0.12% lactic acid, 0.26% carboxymethyl chitosan, 0.4% tocopheryl acetate, 0.5% 1,2-hexanediol, 0.5% β-cyclodextrin, 2% hydrolyzed royal jelly protein, 1.4% peony bark extract, 1.35% hydroxypropyl cellulose, 1.4% gelatin, 1% beeswax, and the balance being water.

[0070] Comparative Example 4 The difference between Comparative Example 4 and Example 1 is that Comparative Example 4 does not contain hydrolyzed royal jelly protein (the total amount of hydrolyzed lupin protein, hydrolyzed royal jelly protein, and peony bark extract is the same), while everything else is the same.

[0071] An anti-ovarian aging gel comprises the following components by weight percentage: 0.12% lactic acid, 0.26% carboxymethyl chitosan, 0.4% tocopheryl acetate, 0.5% 1,2-hexanediol, 0.5% β-cyclodextrin, 1.75% hydrolyzed lupin protein, 1.65% peony bark extract, 1.35% hydroxypropyl cellulose, 1.4% gelatin, 1% beeswax, and the balance being water.

[0072] Comparative Example 5 The difference between Comparative Example 5 and Example 1 is that Comparative Example 5 does not contain peony bark extract (the total amount of hydrolyzed lupin protein, hydrolyzed royal jelly protein, and peony bark extract is the same), while everything else is the same.

[0073] An anti-ovarian aging gel comprises the following components by weight percentage: 0.12% lactic acid, 0.26% carboxymethyl chitosan, 0.4% tocopheryl acetate, 0.5% 1,2-hexanediol, 0.5% β-cyclodextrin, 1.45% hydrolyzed lupin protein, 1.95% hydrolyzed royal jelly protein, 1.35% hydroxypropyl cellulose, 1.4% gelatin, 1% beeswax, and the balance being water.

[0074] Comparative Example 6 The difference between Comparative Example 6 and Example 1 is that the peony bark extract of Comparative Example 6 is different from that of Example 1, but all other aspects are the same.

[0075] The preparation method of the peony bark extract is as follows: (1) Wash the peony bark, dry it to constant weight, pulverize it to 200 mesh to obtain peony bark powder, add the peony bark powder to an ethanol solution with a volume concentration of 60%, extract at 70℃ for 2 hours, filter, dry to obtain peony bark extract, the solid-liquid ratio of the peony bark powder to the ethanol solution is 1g:10mL.

[0076] Comparative Example 7 The difference between Comparative Example 7 and Example 1 is that the peony bark extract in Comparative Example 7 is different from that in Example 1, but everything else is the same.

[0077] The preparation method of the peony bark extract is as follows: (1) Wash the peony bark, dry it to constant weight, pulverize it to 200 mesh to obtain peony bark powder, add the peony bark powder to water, extract it at 70℃ for 2 hours, filter it, dry it to obtain peony bark extract, and the solid-liquid ratio of the peony bark powder to water is 1g:10mL.

[0078] Test case 1. Stability Testing The gels from the examples and comparative examples were placed at 25 and 45°C for 30 days, respectively, and their stability was observed (whether flocculation, precipitation, stratification, etc. occurred).

[0079] Table 1

[0080] 2. Efficacy Test: One hundred female SD mice with normal estrous cycles and a weight of 150±5g were selected and injected intraperitoneally with cyclophosphamide 28mg / kg daily for 6 consecutive days to establish a premature ovarian failure model.

[0081] Eighty-eight mice that successfully developed the model were randomly divided into 11 groups of eight each: ten test groups and one model group. The experimental groups were administered the gel prepared in the examples and comparative examples by gavage, while the model group was administered physiological saline. The dosage was 50 mg / kg, once a day for 30 consecutive days. In addition, eight normal mice were administered physiological saline by gavage in the same manner as above as a blank control group.

[0082] After the experiment, the levels of progesterone and E2 in the serum were measured using a progesterone reflex immunoassay kit and an estradiol radioimmunoassay kit.

[0083] Table 2

[0084] As can be seen from Table 2, the gel described in this application can effectively increase the content of progesterone and E2, and has a good anti-ovarian aging effect.

[0085] Finally, it should be noted that the above embodiments are used to illustrate the technical solutions of the present invention and not to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. An anti-ovarian aging gel, characterized in that, It comprises the following components by weight percentage: 0.05-0.2% lactic acid, 0.1-0.4% stabilizer, 0.2-0.6% tocopheryl acetate, 0.2-0.6% 1,2-hexanediol, 0.3-0.6% sustained-release agent, 0.9-1.2% hydrolyzed lupin protein, 0.8-1.6% hydrolyzed royal jelly protein, 0.75-1.3% peony bark extract, 1-1.5% thickener, 0.5-2% gelatin, 0.5-1.2% beeswax, and the balance being water.

2. The anti-ovarian aging gel according to claim 1, characterized in that, The thickener is at least one of xanthan gum, microcrystalline cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, and methyl cellulose.

3. The anti-ovarian aging gel according to claim 1, characterized in that, The stabilizer is carboxymethyl chitosan.

4. The anti-ovarian aging gel according to claim 1, characterized in that, The sustained-release agent is β-cyclodextrin.

5. The anti-ovarian aging gel according to claim 1, characterized in that, The preparation method of the peony bark extract is as follows: (1) Peony bark powder was subjected to supercritical extraction to obtain the extract; (2) The extract was separated by passing it through a macroporous adsorption resin and dried to obtain the peony bark extract.

6. The anti-ovarian aging gel according to claim 5, characterized in that, The particle size of the peony bark powder is 50-500 mesh.

7. The anti-ovarian aging gel according to claim 5, characterized in that, The supercritical extraction uses an ethanol solution with a volume concentration of 60-85% as an entrainer, CO2 as the extractant, a CO2 flow rate of 60-75 mL / min, an extraction temperature of 35-42℃, an extraction pressure of 18-24 MPa, and an extraction time of 50-100 min.

8. The anti-ovarian aging gel according to claim 5, characterized in that, The separation of the extract by passing it through a macroporous adsorption resin specifically involves: passing the extract through the macroporous adsorption resin at a flow rate of 0.5~2 BV / h, eluting at a rate of 0.8~1.5 BV / h, washing with water for 0.8~1.5 BV, and then washing with an ethanol solution with a volume concentration of 60~85wt% for 1~2 BV, and collecting the ethanol eluent.

9. The anti-ovarian aging gel according to claim 8, characterized in that, The macroporous adsorption resin is HPD-300 macroporous adsorption resin.

10. A method for preparing the anti-ovarian aging gel according to any one of claims 1 to 9, characterized in that, Includes the following steps: Stabilizer, gelatin, beeswax, slow-release agent, thickener and water are mixed evenly at 50~85℃, cooled to 30~45℃, and then lactic acid, tocopheryl acetate, hydrolyzed lupin protein, hydrolyzed royal jelly protein and peony bark extract are added and stirred evenly to obtain anti-ovarian aging gel.

Images